A5080644436- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Pneumonia and Respiratory Infections
- Metabolism, Diabetes, and Cancer
- Cancer survivorship and care
- Chemotherapy-induced cardiotoxicity and mitigation
- Mast cells and histamine
- Ferroptosis and cancer prognosis
- Heart Failure Treatment and Management
- Diabetes Treatment and Management
- Urological Disorders and Treatments
- Bacterial Infections and Vaccines
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Nosocomial Infections in ICU
- Bladder and Urothelial Cancer Treatments
- Sepsis Diagnosis and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer, Lipids, and Metabolism
- Cancer, Stress, Anesthesia, and Immune Response
- Semiconductor materials and devices
- Respiratory viral infections research
- Inflammatory Biomarkers in Disease Prognosis
- COVID-19 and healthcare impacts
- Cancer Treatment and Pharmacology
London School of Hygiene & Tropical Medicine
2022-2024
National Taiwan University Hospital
2023-2024
Kuang Tien General Hospital
2022-2023
Chung Shan Medical University
2022
Museum of Heilongjiang Province
2021
Abstract Background and Aim Patients with type 2 diabetes mellitus (T2DM) have a higher risk of colorectal cancer (CRC), those diagnosed CRC poorer prognosis compared individuals normal glucose levels. The inhibition sodium‐glucose cotransporter (SGLT2) channels has been associated reduction in tumor proliferation preclinical studies. We aimed to investigate the impact inhibitors (SGLT2i) on outcome T2DM patients cancer. Methods performed retrospective cohort study comprising adult...
Objectives Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce heart failure (HF) in at-risk patients and may possess antitumour effects. We examined the effect of SGLT2i on HF mortality among with cancer diabetes. Methods This was a retrospective propensity score-matched cohort study involving adult type 2 diabetes mellitus diagnosed between January 2010 December 2021. The primary outcomes were hospitalisation for incident all-cause mortality. secondary serious adverse events...
Abstract Objectives Immune checkpoint inhibitors are associated with adverse cardiovascular events. However, there no data characterizing events among Asians on immune inhibitors. We aim to determine the incidence and risk of cardiac in an Asian population. Methods performed a retrospective, propensity score-matched cohort study at two tertiary referral centers Taiwan. inhibitor users were matched non-immune based predetermined clinical variables. The primary outcome was major events,...
Statins are associated with improved survival outcomes in patients receiving immune checkpoint inhibitors (ICIs), but the impact of lipophilic and hydrophilic statin properties on patient is unknown.We aim to investigate if statins clinical ICIs.We conducted a retrospective cohort study at two tertiary referral centers Taiwan comprising ICIs between January 2015 December 2021. We compared comparative effect outcomes. The primary outcome was overall (OS) secondary progression-free (PFS).Among...
Certain angiotensin receptor blockers (ARBs) have peroxisome proliferator-activated receptor-γ (PPAR-γ) activation property, which has been associated with improved programmed cell death ligand 1 blockade and cytotoxic T lymphocyte-mediated antitumor activity.We conducted a retrospective cohort study to investigate the impact of PPAR-γ-activating ARBs on patient survival in patients treated immune checkpoint inhibitors (ICIs) across all types cancers.A total 167 receiving both were included....
Objective Statins have been demonstrated to improve outcomes in patients receiving immune checkpoint blockade (ICB). This study aimed investigate whether the timing of statin administration influences ICB.